Operational Excellence (OPEX) Daily Briefing – Wednesday, September 10, 2025: Novo Nordisk Cuts 9,000 Jobs: OPEX Lessons for Every Business.
Điểm Tin Operational Excellence (OPEX) Mỗi Ngày – Thứ Tư, ngày 10/09/2025: Novo Nordisk cắt giảm 9.000 việc làm: Bài học OPEX cho mọi doanh nghiệp.
Welcome to my unique weekday article for the paid subscriber-only edition.
Operational Excellence (OPEX) Daily Briefing – issued on weekdays (Monday to Friday).
Điểm tin Operational Excellence (OPEX) hằng ngày (phát hành các ngày thứ Hai đến thứ Sáu).
This is the bilingual post in English and Vietnamese. Vietnamese is below.
Đây là bài viết song ngữ Anh-Việt. Tiếng Việt ở bên dưới.
Don’t forget the unique BizDecoded series.
🔍 20 Brands, 20 Deep Dives: The Business Behind the Money Machine
Starting from August 20, 2025, get ready for a masterclass like no other.
English:
What happened?
On September 10, 2025, Danish pharmaceutical giant Novo Nordisk announced a plan to cut 9,000 jobs, equivalent to more than 11% of its global workforce. Around 5,000 positions will be affected in Denmark. The goal is to streamline operations, accelerate decision-making, and focus on core areas such as diabetes, obesity treatment, and next-generation biotechnology. The company expects to save about 8 billion Danish kroner annually, while incurring a one-time restructuring cost of 9 billion kroner in Q3 2025.
Market impact:
Novo Nordisk shares have fallen nearly 46% since the beginning of the year, with market capitalization dropping from around USD 650 billion to just USD 181 billion. However, immediately after the layoff announcement, shares rose slightly by 2–3%, as investors viewed the move as necessary to restore margins and improve operational efficiency.
Why is the risk so high?
The global weight-loss drug market is booming but more competitive than ever:
Eli Lilly, with its drug Mounjaro, is outperforming and capturing market share.
Cheaper generic drugs from India and China are putting heavy pressure on Wegovy and Ozempic, Novo’s flagship products.
Rising R&D and operational costs are colliding with shareholder expectations for sustainable profitability.
Restructuring rationale:
The job cuts align with the strategy of new CEO Mike Doustdar, who has emphasized the need to build a performance-driven culture, eliminate bureaucratic structures, and selectively allocate resources to strategic business areas.
This event shows that even industry leaders must restructure to adapt. It reflects a broader trend in pharmaceuticals: becoming leaner, more focused, and continuously innovative to maintain competitive advantage.